30 Apr 2020 10:34
Result of General Meeting and Change of Name
Oxford, UK - 30 April 2020: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, today announces that at the General Meeting held earlier today, the Resolutions proposed were duly passed by shareholders. The Company will formally change its name to Circassia Group plc in the coming days, a further announcement will be made ahead of the name change being formally implemented. Upon the change of name the Company's TIDM will remain CIR and the Company's website address will continue to be www.circassia.com.
The full text of the resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 15 April 2020 which is available on the Company's website www.circassia.com.
The transfer to AstraZeneca of the U.S. commercial rights to Tudorza® and Duaklir® together with certain ancillary rights and assets, from Circassia remains subject to competition law clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The Company filed for Hart-Scott-Rodino clearance on 23 April 2020.
Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the shareholder circular.
Contacts
Circassia Ian Johnson, Executive Chairman Michael Roller, Chief Financial Officer
| c/o Peel Hunt
|
Peel Hunt (Nominated Adviser and Joint Broker) James Steel / Oliver Jackson
| Tel: +44 (0) 20 7418 8900
|
finnCap (Joint Broker) Geoff Nash / Alice Lane | Tel: +44 (0) 20 7220 0500 |
Numis Securities (Joint Broker) James Black / Duncan Monteith | Tel: +44 (0) 20 7260 1000
|